BioMarin delivered $1 billion in third-quarter revenue, up 32% year over year, driven by 44% growth in its metabolic conditions portfolio and 12% growth from achondroplasia therapy Voxzogo. Management narrowed the midpoint of its 2026 revenue outlook by 128 basis points to $3.85 billion.
BioMarin's approved drugs have been granted orphan-drug status in the US and the EU, providing them with at least seven and 10 years of market exclusivity, respectively.
Diagnosis of very rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.
Metric | BMRN | SNY | PFE |
|---|---|---|---|
Price/Earnings (Normalized) | 20.87 | 12.47 | 13.45 |
Price/Book Value | 1.77 | 1.40 | 1.87 |
Price/Sales | 3.07 | 1.96 | 2.63 |
Price/Cash Flow | 11.29 | 8.36 | 11.33 |
Metric | BMRN | SNY | PFE |
|---|---|---|---|
Quick Ratio | 1.13 | 0.21 | 1.00 |
Current Ratio | 2.44 | 1.12 | 1.42 |
Interest Coverage | 0.90 | 9.10 | 2.39 |
Metric | BMRN | SNY | PFE |
|---|---|---|---|
Return on Assets (Normalized) | 5.51% | 8.44% | 8.49% |
Return on Equity (Normalized) | 8.37% | 15.62% | 19.73% |
Return on Invested Capital (Normalized) | 6.89% | 12.02% | 12.71% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$#<&?f? | LOCK|#LNb | $140B | |||
| Moderna Inc MRNA | LOCK|&cVK#g | LOCK|jQ& | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%^t>m<g | LOCK|nx<l< | $95B | |||
| argenx SE ADR ARGX | LOCK|<%TG#xb | LOCK|fsn | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|hL?PWX$ | LOCK|@< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|KQ$#^>qj | LOCK|PTW@& | $31B | |||
| Incyte Corp INCY | LOCK|Gb$^p< | LOCK|f@ | $25B | |||
| BioNTech SE ADR BNTX | LOCK|$w%b$@ | LOCK|XK | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|pr^Gq# | LOCK|lR&G% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|dwTldN | LOCK|hh | $16B |
United States